Insider filing · IMDX

Broadwood Partners, L.P. bought $3.0M of Insight Molecular Diagnostics (IMDX)

Executed Feb 10, disclosed Feb 13, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Feb 12), the stock returned -11.2% (delay-adjusted); from the execution session (Feb 10), -26.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

BP Broadwood Partners, L.P. Director profile →

Broadwood Partners, L.P. (Director) filed 7 Form 4 reports as a reporting entity in the trailing twelve months (7 purchases, 0 sales), most often in STAA. Across 7 priced purchase filings, the average 21-session return was +18.0% from execution and +16.5% from disclosure (delay-adjusted; derived). The largest single filing was $41.1M of STAA (1,500,000 sh across 3 lots, as filed), executed Nov 19 2025.

IMDX IMDX IMDX · 3 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→